Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for th... Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.03 | 0.244897959184 | 12.25 | 13.2 | 11.96 | 8165 | 12.55111141 | DR |
| 4 | -0.58 | -4.5101088647 | 12.86 | 13.77 | 11.84 | 12592 | 12.88344959 | DR |
| 12 | -3.29 | -21.1303789338 | 15.57 | 18.41 | 11.8301 | 15047 | 14.78137385 | DR |
| 26 | -4.87 | -28.3965014577 | 17.15 | 21.34 | 11.8301 | 22822 | 16.46371457 | DR |
| 52 | 0.39 | 3.28006728343 | 11.89 | 21.34 | 9.5354 | 17522 | 15.73383473 | DR |
| 156 | 0.21 | 1.73985086993 | 12.07 | 21.34 | 6.65 | 8860 | 13.60482375 | DR |
| 260 | 0.18 | 1.48760330579 | 12.1 | 21.34 | 6.1 | 8263 | 12.80908344 | DR |
flsh56
3分前
Steady_T
4分前
jimr1717
4分前
StockInfo11
4分前
Vitamin310
6分前
jimr1717
6分前
WhatMoney?
6分前
jimr1717
8分前
peafunke
8分前
BIOChecker4
10分前
WhatMoney?
12分前
jimr1717
13分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。